Bluebird's Zynteglo trials set to resume, putting gene therapy back on flight path to FDA filing

Bluebird's Zynteglo trials set to resume, putting gene therapy back on flight path to FDA filing

Source: 
Fierce Pharma
snippet: 

Bluebird Bio's beta-thalassemia gene therapy Zynteglo has struggled to spread its wings, and a recent clinical pause certainly didn't help. But with studies on several bluebird drugs set to resume, Zynteglo could be looking at clearer skies ahead.